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Sir,
We read with great interest the published article by Kallio et al
(2003) in the British Journal of Cancer on the association between
the location of EGFR immunostaining and overall survival in renal
cell carcinoma (RCC) patients. In this paper, the authors have
reported that overall survival was significantly longer (P¼0.004)
in patients with prominent membranous EGFR expression
compared to patients with either EGFR-negative tumours or
tumours with predominantly cytoplasmic EGFR staining (Kallio
et al, 2003). This is an important finding, as the expression of
membranous EGFR has often been associated with a poor
prognosis in cancer patients (Lager et al, 1994; Moch et al,
1997), while other studies have found either no association
between EGFR expression and prognosis (Hofmockel et al, 1997)
or more recently an association between the expression of
cytoplasmic EGFR and poor prognosis in RCC patients (Langner
et al, 2004).
To our knowledge, the paper by Kallio et al is the first paper to
describe an association between prominent membranous EGFR
immunostaining and longer overall survival in RCC patients.
However, there is a conflicting statement in the Materials and
Methods section of the paper by Kallio et al that prevents us from
accepting their conclusion and the authors need to clarify/rectify
accordingly. In the immunohistochemical staining section of the
Materials and Methods, Kallio et al stated the use of a polyclonal
rabbit anti-EGFR variant III antibody (EGFRvIII) for EGFR
immunostaining. The EGFRvIII is a ligand-independent, constitu-
tively active and mutated form of EGFR (Pederson et al, 2001). Did
the author use the rabbit anti-EGFRvIII antibody in their study
and if so does it crossreact with the EGFR? Could Kallio et al
clarify/rectify whether the prominent membranous EGFRvIII
immunostaining in that study was associated with a good
prognosis in patients with RCC? While no clear association has
been found between the expression of the EGFR and response to
the EGFR inhibitors in cancer patients, including patients with
RCC, the expression of membranous EGFR and/or EGFRvIII in
RCC patients would, however, make them an ideal target for
therapy with the anti-EGFR antibodies (Modjtahedi et al, 2003;
Dawson et al, 2004; Rowinsky et al, 2004; Dancey, 2004). We would
appreciate clarification from Kallio et al.
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